A top analyst sees 'inflection point' in the other big vaccine race taking pharma by storm

Beneath the Covid-19 vaccine race, there’s another vaccine race in full swing, with billions on the line and many of the same leading players edging for first: the race for an RSV vaccine.

Although the seasonal infection can be deadly in young children and the elderly, scientists have failed for decades to come up with a vaccine. An early trial in the 1960s ended in disaster, after it appeared the vaccine actually helped the virus infect cells. Recent advancements, though, have renewed interest in what could be a $10 billion market, bringing in efforts from major developers, including Pfizer, Moderna, J&J, Merck, Sanofi and GlaxoSmithKline.